OCS Stock Summary and Trading Ideas (Oculis Holding Ag - | NASDAQ:OCS)

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.

As of March 31, 2026, OCS stock price climbed to $26.59 with 95,929 million shares trading.

OCS has a beta of 0.74, meaning it tends to be less sensitive to market movements. OCS has a correlation of 0.07 to the broad based SPY ETF.

OCS has a market cap of $1.54 billion. This is considered a Small Cap stock.

Last quarter Oculis Holding Ag - reported $514,161 in Revenue and -$.53 earnings per share. This beat revenue expectation by $244,161 and missed earnings estimates by -$.10.

In the last 3 years, OCS traded as high as $30.68 and as low as $7.41.

The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, ONEQ, GWX, SMLV, FPXE.

OCS has outperformed the market in the last year with a price return of +38.6% while the SPY ETF gained +16.6%. OCS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +33.4% and +2.2%, respectively, while the SPY returned -6.5% and -4.0%, respectively.

OCS support price is $23.69 and resistance is $25.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.